Current and future treatment approaches for neuromyelitis optica
Open Access
- 4 March 2011
- journal article
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 4 (2), 111-121
- https://doi.org/10.1177/1756285611398939
Abstract
Neuromyelitis optica (NMO) is an inflammatory disease of the central nervous system (CNS) characterized by severe attacks of optic neuritis and myelitis, and which, unlike multiple sclerosis (MS), commonly spares the brain in the early stages. NMO used to be considered as a special form of MS. During the past 10 years, however, the two diseases have been shown to be clearly different. NMO is a B-cell-mediated disease associated with anti-aquaporin-4 antibodies in many cases and its pathophysiology seems to be near the acute lesion of necrotizing vasculitis. Assessment of prevalence shows that NMO is far less frequent than MS, which explains the absence of randomized clinical trials and NMO treatment strategies validated by evidence-based medicine. Recently, many data have been published that suggest that the therapeutic option in NMO should be immunosuppressive rather than immunomodulatory drugs. In the present study, after a brief overview of NMO, we review therapeutic studies and propose new therapeutic strategies in the relapse and disease-modifying fields.Keywords
This publication has 66 references indexed in Scilit:
- Management of nonresponse to rituximab in rheumatoid arthritis: Predictors and outcome of re‐treatmentArthritis & Rheumatism, 2010
- T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitisNature Medicine, 2010
- Aquaporin-4–binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2The Journal of Experimental Medicine, 2008
- Biological activities of C1 inhibitorMolecular Immunology, 2008
- Antibody to aquaporin-4 in the long-term course of neuromyelitis opticaBrain, 2008
- Variable responses to rituximab treatment in neuromyelitis optica (Devic’s disease)Neurological Sciences, 2007
- Immunosuppressive therapy is more effective than interferon in neuromyelitis opticaMultiple Sclerosis Journal, 2007
- Clinical Pharmacokinetics of CyclophosphamideClinical Pharmacokinetics, 2005
- The treatment of inflammatory bowel disease with 6‐mercaptopurine or azathioprineAlimentary Pharmacology & Therapeutics, 2001
- Pharmacokinetics and Metabolism of MitoxantroneClinical Pharmacokinetics, 1990